GOSS

Gossamer Bio, Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$0.16

−$0.02−11.11%

Delayed · 2026-09-09T20:00:00.000Z · marketstack

Aug 10, 2026$0.16

−$0.02−9.09%over 1M

Day range45% of range

$0.15$0.17

Session

Previous close: $0.18
Open: $0.15
Volume: 23.5M
Avg volume: -
Day high: $0.17
Day low: $0.15

Fundamentals

Visualize fundamentals and more

Market cap: 51.2M
P/E ratio: -
EPS (TTM): -$0.38
Dividend yield: -
Beta: 1.97
Shares outstanding: 320.01M

Source SEC EDGAR · 9/10/2026

Risk factors, year on year

Item 1AMarch 2026 10-KMarch 2025as filed.

added: 63
dropped: 64
re-drafted: 47

Out of 303 passages in this year’s Item 1A.

New this year

• The results from the PROSERA Phase 3 clinical trial may not be sufficient to support FDA approval or continued development of seralutinib, which would materially and adversely harm our business.

126 more passages, included withBespoke

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Companies like Gossamer Bio, Inc.

Also filed under Biotechnology, ranked by how closely they sit beside GOSS.

MRNAModerna, Inc.
ATAIAtaiBeckley Inc.
ALNYALNYLAM PHARMACEUTICALS, INC.
REGNREGENERON PHARMACEUTICALS, INC.
VRTXVERTEX PHARMACEUTICALS INC / MA
INSMINSMED Inc

Ask about Gossamer Bio, Inc.

The assistant answers from what GOSS has actually filed: 9 annual reports filed with the SEC and 2 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from GOSS's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding Gossamer Bio, Inc., and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

What an account lets you do with Gossamer Bio, Inc.

Separate the decisions from the paperwork
Every Form 4 GOSS insiders have filed, with vesting and automatic tax sales struck out: what's left is the buys and sells somebody actually chose to make.
Every filingMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: who added, who trimmed, who walked away.
Every position they holdMeasure
Interrogate the filing, not the internet
Ask anything about Gossamer Bio, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free accountSee what the paid plans add

Free, no card, and it does not expire.